Up a level |
Al-Batran, Salah-Eddin and Schuler, Martin H. and Zvirbule, Zanete and Manikhas, Georgiy and Lordick, Florian and Rusyn, Andriy and Vynnyk, Yuriy and Vynnychenko, Ihor and Fadeeva, Natalia and Nechaeva, Marina and Dudov, Assen and Gotovkin, Evgeny and Pecheniy, Alexander and Bazin, Igor and Bondarenko, Igor and Melichar, Bohuslav and Mueller, Christian and Huber, Christoph and Tureci, Oezlem and Sahin, Ugur (2016) FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology, Vol 34 (No18_s). P.-LBA4001. ISSN 0732-183X (Print) ; 1527-7755 (Electronic) ; 0732-183X (Linking)